COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.

Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M, CONFIDENCE investigators

Open source

DOI: 10.1093/ndt/gfaf022
Published: 2025 Aug 1
Container: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/ndt/gfaf022,
  title = {COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.},
  author = {Agarwal R and Green JB and Heerspink HJL and Mann JFE and McGill JB and Mottl AK and Rosenstock J and Rossing P and Vaduganathan M and Brinker M and Edfors R and Li N and Scheerer MF and Scott C and Nangaku M and CONFIDENCE investigators},
  year = {2025},
  journal = {Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  doi = {10.1093/ndt/gfaf022},
  url = {https://doi.org/10.1093/ndt/gfaf022}
}

RIS

TY  - JOUR
TI  - COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
AU  - Agarwal R
AU  - Green JB
AU  - Heerspink HJL
AU  - Mann JFE
AU  - McGill JB
AU  - Mottl AK
AU  - Rosenstock J
AU  - Rossing P
AU  - Vaduganathan M
AU  - Brinker M
AU  - Edfors R
AU  - Li N
AU  - Scheerer MF
AU  - Scott C
AU  - Nangaku M
AU  - CONFIDENCE investigators
PY  - 2025
JO  - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
DO  - 10.1093/ndt/gfaf022
UR  - https://doi.org/10.1093/ndt/gfaf022
ER  -

APA

R, A., JB, G., HJL, H., JFE, M., JB, M., AK, M., J, R., P, R., M, V., M, B., R, E., N, L., MF, S., C, S., M, N., & investigators, C. (2025). COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. https://doi.org/10.1093/ndt/gfaf022

Source records

pubmed · retrieved 2026-09-25T05:22:13.548Z